12:00 AM
Dec 03, 2012
 |  BC Week In Review  |  Company News  |  Other News

Spherix endocrine/metabolic news

Spherix said in its 3Q12 earnings last month that it plans to re-examine its business strategies and explore strategic alternatives. The company, which also said it expanded its board to eight from six members, said the re-examination may result in the divestiture or winding down of certain...

Read the full 211 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >